RTN4 and myeloid sarcoma: The inhibitory effect of Nogo-A on myelination and OPC recruitment to lesion sites, could potentially be a trigger to pathological events that govern axonal degeneration, and so antagonizing Nogo-A function in the pathological tissue milieu, may be of therapeutic interest for MS.